Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

SELL
$6.7 - $24.21 $735,686 - $2.66 Million
-109,804 Reduced 60.34%
72,176 $1.74 Million
Q4 2022

Jan 27, 2023

SELL
$4.52 - $10.57 $179,086 - $418,793
-39,621 Reduced 17.88%
181,980 $0
Q3 2022

Nov 01, 2022

SELL
$3.43 - $5.62 $14,351 - $23,514
-4,184 Reduced 1.85%
221,601 $997,000
Q2 2022

Aug 08, 2022

BUY
$3.65 - $7.3 $20,878 - $41,756
5,720 Added 2.6%
225,785 $903,000
Q1 2022

May 05, 2022

BUY
$3.4 - $7.88 $47,090 - $109,138
13,850 Added 6.72%
220,065 $1.61 Million
Q4 2021

Feb 14, 2022

SELL
$5.59 - $7.39 $196,745 - $260,098
-35,196 Reduced 14.58%
206,215 $1.16 Million
Q3 2021

Nov 09, 2021

BUY
$5.66 - $8.33 $31,056 - $45,706
5,487 Added 2.33%
241,411 $1.55 Million
Q2 2021

Jul 29, 2021

SELL
$6.71 - $11.04 $75,628 - $124,431
-11,271 Reduced 4.56%
235,924 $1.99 Million
Q1 2021

May 14, 2021

BUY
$10.12 - $19.45 $799 - $1,536
79 Added 0.03%
247,195 $2.59 Million
Q4 2020

Feb 16, 2021

BUY
$11.79 - $18.94 $191,504 - $307,642
16,243 Added 7.04%
247,116 $4.19 Million
Q3 2020

Nov 16, 2020

BUY
$10.34 - $15.2 $878,041 - $1.29 Million
84,917 Added 58.18%
230,873 $2.96 Million
Q2 2020

Aug 14, 2020

BUY
$7.81 - $17.0 $84,379 - $183,668
10,804 Added 7.99%
145,956 $2.06 Million
Q1 2020

May 15, 2020

BUY
$5.42 - $17.75 $415,085 - $1.36 Million
76,584 Added 130.76%
135,152 $1.24 Million
Q4 2019

Jan 29, 2020

BUY
$5.84 - $14.9 $342,037 - $872,663
58,568 New
58,568 $873,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0

About Provention Bio, Inc.


  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Rice Hall James & Associates, LLC Portfolio

Follow Rice Hall James & Associates, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rice Hall James & Associates, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rice Hall James & Associates, LLC with notifications on news.